RCUS Arcus Biosciences, Inc. Insider Trading

RCUS President sells 31.8K shares ($681.3K) across 3 transactions at blended $21.41; holds 922.2K post-sale in unprofitable biotech company.

Jaen Juan C., President of Arcus Biosciences, executed 3 separate sales totaling 31,823 shares for $681,341.82 on 2026-01-05 at an average price of $21.41, reducing holdings by 3.3% to 922,240 shares. The stock currently trades at $23.20, placing the transaction prices 7.7% below current market levels. Arcus is a deeply unprofitable biotech company with -$135,000,000.00 net income on $26,000,000.00 quarterly revenue, operating at a substantial loss while exhibiting strong top-line growth of 120.5% year-over-year. The 90-day price performance context is mixed: the stock has risen 53.0% over 90 days but fallen 10.1% over the last 30 days, creating a volatile environment near its 52-week high of $26.10. Across his same-ticker history at RCUS, the President has executed 5 prior sales, none of which have yet generated measurable 90-day outcomes, leaving the pattern of timing at this specific ticker unresolved.

CEO Terry Rosen sold 54,691 shares (54.7K) for $1.2M across 2 sales at blended $22.01; stock up +77.5% in 90 days

Terry Rosen, CEO of Arcus Biosciences, executed 2 separate sales totaling 54,691 shares for $1,203,959.00 on 2025-12-16 and 2025-12-17, reducing his position by 2.4% to 2,194,809 shares post-transaction. The sales occurred as the stock traded at the blended price of $22.01, following a sharp +77.5% gain over the prior 90 days and within 15.8% of its 52-week high of $26.10. While the company is unprofitable (net income of $-135,000,000.00 on quarterly revenue of $26,000,000.00), it is experiencing strong annual revenue growth of +120.5%. His sole prior trade at this ticker (a February 2025 buy) showed negative 90-day returns of -10.3%, and his cross-ticker track record exhibits a 0% win rate on buys with average 90-day returns of -10.3%, though this timing does not apply to his current sell activity. The timing of this sale relative to the stock's recent 77.5% surge and proximity to all-time highs warrants examination against his historical execution pattern.

President Jaen Juan C. sold 82,997 shares of RCUS at $24.71; holding drops to 954,063 shares post-sale.

Jaen Juan C., President of Arcus Biosciences, executed an open-market sale of 82,997 shares (83.0K shares) on 2025-12-04 at $24.71, reducing his holdings by 8.0% to 954.1K shares. The sale occurred near the stock's 52-week high of $26.10 (-2.5%), following a robust 30-day gain of +28.9% and 90-day advance of +108.8%. Arcus reported a quarterly revenue of $26.0M but remains unprofitable with a $-135.0M net loss; however, the company has achieved +120.5% annual revenue growth. Across his cross-ticker track record, the insider's 9 prior sells show a 100.00% well-timed rate at the 90-day mark, though at RCUS specifically, his 5 prior trades show no measurable 90-day outcomes yet and mixed 30-day results. The timing proximity to the 52-week high and the strength of recent price momentum provide context for this discretionary reduction in equity exposure.

President Juan C. Jaen sold 50,000 shares at $20.26 avg ($1.0M) on Nov 17–18; RCUS stock near 52-week high, up 92.9% in 90 days.

Jaen executed 3 separate sales totaling 50,000 shares for $1,012,764.29 over two trading days as RCUS approached its 52-week high of $20.35, now trading at $20.22. The stock has rallied 92.9% over 90 days and 15.7% over 30 days, creating a window at elevated valuations. Despite strong recent price action, the company remains unprofitable (net income of $-135,000,000.00 in the latest full fiscal year) while generating $26,000,000.00 in quarterly revenue. Jaen's cross-ticker track record shows a 100.00% well-timed rate across 6 prior sells, though his measurable prior transactions at RCUS (5 trades, most from October 2025 with outcomes not yet measurable) offer limited timing precedent at this specific ticker.

RCUS COO Jarrett Jennifer sold 50,291 shares at $18.97 on 2025-11-07; stock has risen 20.2% in 30 days and 101.8% in 90 days from sale date.

Jennifer's sale of 50,291 shares at $18.97 reduced her holdings by 19.0% from 264,523 to 214,232 shares, representing a $954,065.53 transaction. The timing is notable: across her prior 5 open-market sells (cross-ticker), a 90-day well-timed rate of 100.00% indicates her previous sales have historically occurred before subsequent declines; however, at RCUS specifically, 3 of 3 measurable prior sales at this ticker also achieved negative 90-day returns (-6.1%, -9.3%, -21.4%), following the same pattern. Yet this current sale executed at $18.97 is now underwater relative to the current price of $20.00, and the stock has posted a 30-day return of +20.2% and 90-day return of +101.8% from the transaction date, contrasting with her established historical pattern. Arcus Biosciences remains unprofitable (net income $-135,000,000.00 on quarterly revenue of $26,000,000.00) despite strong annual revenue growth of +120.5%, creating fundamental volatility that may explain the sharp post-sale appreciation.

President Jaen Juan C. sold 96.9K shares ($2.0M) at $20.76 avg; stock +48.5% in 30d, +120.4% in 90d from lows

Jaen Juan C., President of Arcus Biosciences, executed 4 separate sales totaling 96,859 shares for $2,010,578.37 on 2025-10-28 and 2025-10-29, reducing his holdings by 8.2%. The stock is trading near its 52-week high ($20.29) with strong recent momentum (+48.5% over 30 days, +120.4% over 90 days from the $6.87 low). Notably, his prior two sales at RCUS in February 2024 both proved well-timed at the 90-day mark (30d returns of -6.1% and -9.2%, 90d returns of -19.8% and -19.6%), and his cross-ticker track record shows a 100% well-timed rate on sells. However, the company remains unprofitable with a $-135.0M net loss on $26.0M quarterly revenue, despite 120.5% annual revenue growth. The timing of this sale—at near-peak valuations and amid ongoing losses—warrants attention to whether it reflects conviction about near-term valuation levels or capital allocation decisions by senior management.

COO Jarrett Jennifer sold 50,292 shares at $14.92 blended average for $750,412.12 at RCUS, reducing holdings 19.0%.

Jarrett Jennifer, Chief Operating Officer at Arcus Biosciences, executed 2 separate sales totaling 50,292 shares for $750,412.12 on 2025-10-06 and 2025-10-08, reducing her post-transaction holdings to 214,232 shares from 264,524 shares. The blended average sale price of $14.92 occurred as the stock trades near its current level of $15.05, up 31.6% over the past 30 days and 57.8% over the past 90 days—a strong recent rally. Her prior 3 sales at RCUS were all well-timed at the 90-day mark (negative average 90-day return of -19.8%, -19.7%, and -21.4%), establishing a consistent pattern of selling before subsequent declines at this specific ticker. Her cross-ticker track record shows a 100.00% well-timed rate across 3 prior sells, though those exhibited notably weaker performance (avg 90d return -20.3% vs peers). The company itself is unprofitable with full-year net income negative, though revenues grew 120.5% year-over-year to $160,000,000, presenting a typical high-growth biotech risk profile. The materiality of this 19.0% reduction in holdings, combined with the insider's demonstrated track record of well-timed sales specifically at RCUS and the current elevated stock momentum, warrants investor attention to the underlying fundamentals.

CEO Rosen bought 19,800 shares of RCUS at $10.18 on 2025-02-27; stock down -51.0% from 52-week high; cluster pattern with 2 other insiders buying in past 14 days

CEO Terry J Rosen purchased 19,800 shares at $10.18, increasing his holdings from 2,534,360 to 2,554,160 shares. This purchase occurs while RCUS trades -51.0% from its 52-week high and down -24.5% over the past 30 days, alongside a cluster of 2 other insider purchases within the same 14-day window. The company carries negative fundamentals (net income of $-92,000,000 on $48,000,000 quarterly revenue), reflecting ongoing losses despite 120.5% annual revenue growth. The convergence of CEO buying, multiple insider accumulation, and depressed valuation relative to 52-week levels warrants investor attention to whether leadership views the current price as mispriced or whether broader operational challenges persist.

RCUS Director bought 20,000 shares at $10.06; holdings +238.1%; cluster buy pattern with 2 others in 14 days.

KANEKO YASUNORI, as Director, purchased 20,000 shares at $10.06 on 2025-02-27, expanding his holdings by +238.1% from 8,400 to 28,400 shares. This transaction occurred as the stock trades 51.0% below its 52-week high of $20.18 and has declined 24.5% over 30 days and 36.0% over 90 days. Notably, two other insiders also executed purchases within the past 14 days, constituting a cluster buy pattern. The company is unprofitable (net income of $-92,000,000.00 in its most recent full fiscal year) despite showing strong annual revenue growth of +120.5%, and the $1.0B market cap company generated $48.0M in latest-quarter revenue, suggesting early-stage or transitional operations typical of biotech development profiles. The coordinated insider accumulation during a period of significant price decline, combined with multi-executive participation, presents a pattern worth monitoring for its implications regarding internal confidence or strategic positioning.

Gilead Sciences, a 10% owner, acquired 1,363,636 shares of Arcus Biosciences (RCUS) for $15.0M on Feb 18, raising stake to 31.42M shares.

Gilead, already a major stakeholder with 30.06M shares, increased its Arcus position by 1.36M shares at $11.00 per share. The timing occurs as RCUS trades 46.8% below its 52-week high and down 24.0% over 30 days, reflecting substantial recent weakness. Gilead's prior two purchases at RCUS (on 2024-01-29 and 2023-06-28) both resulted in negative 90-day returns of -8.8% and -0.3% respectively, with 0 of 2 prior trades proving well-timed by the 90-day mark. The target company remains unprofitable with a net income loss of $92.0M against quarterly revenue of $48.0M, though it posted 4.5% annual revenue growth. This incremental stake increase follows a track record of underwater timing at this specific ticker.